

Tapan K Bera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6596690/publications.pdf>

Version: 2024-02-01

30
papers

1,134
citations

471061

17
h-index

476904

29
g-index

30
all docs

30
docs citations

30
times ranked

1671
citing authors

#	ARTICLE	IF	CITATIONS
1	Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2202439119.	3.3	8
2	Immunotherapy-based targeting of MSLN activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	11
3	Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity. Molecular Cancer Therapeutics, 2020, 19, 812-821.	1.9	14
4	Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation. Biomolecules, 2020, 10, 1387.	1.8	6
5	Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, 192-199.e1.	1.0	7
6	Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4592-4598.	3.3	14
7	Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. Journal of Immunotherapy, 2019, 42, 119-125.	1.2	4
8	Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3501-E3508.	3.3	44
9	Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins, 2018, 10, 447.	1.5	8
10	Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma. Antibody Therapeutics, 2018, 1, 19-25.	1.2	7
11	Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins, 2018, 10, 210.	1.5	8
12	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunology Research, 2017, 5, 685-694.	1.6	37
13	Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Molecular Cancer Therapeutics, 2016, 15, 1648-1655.	1.9	22
14	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. Leukemia Research, 2014, 38, 1224-1229.	0.4	34
15	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. PLoS ONE, 2014, 9, e104388.	1.1	8
16	POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells. Biochemical and Biophysical Research Communications, 2012, 417, 1271-1274.	1.0	15
17	A model for obesity and gigantism due to disruption of the <i>Ankrd26</i> gene. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 270-275.	3.3	79
18	Selective POTE Paralogs on Chromosome 2 are Expressed in Human Embryonic Stem Cells. Stem Cells and Development, 2008, 17, 325-332.	1.1	19

#	ARTICLE	IF	CITATIONS
19	POTE Paralogs Are Induced and Differentially Expressed in Many Cancers. <i>Cancer Research</i> , 2006, 66, 52-56.	0.4	59
20	Recombinant Immunotoxins in the Treatment of Cancer. , 2004, 248, 503-518.		70
21	NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 3059-3064.	3.3	74
22	Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. <i>Gene</i> , 2004, 337, 45-53.	1.0	43
23	PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3058-3063.	3.3	38
24	MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6997-7002.	3.3	116
25	POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16975-16980.	3.3	75
26	PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. <i>Prostate</i> , 2001, 47, 125-131.	1.2	36
27	GDEP, a new gene differentially expressed in normal prostate and prostate cancer. <i>Prostate</i> , 2001, 48, 231-241.	1.2	31
28	Cse1l Is Essential for Early Embryonic Growth and Development. <i>Molecular and Cellular Biology</i> , 2001, 21, 7020-7024.	1.1	32
29	Mesothelin Is Not Required for Normal Mouse Development or Reproduction. <i>Molecular and Cellular Biology</i> , 2000, 20, 2902-2906.	1.1	198
30	Comparison of Recombinant Immunotoxins against LeYAntigen Expressing Tumor Cells:Â Influence of Affinity, Size, and Stability. <i>Bioconjugate Chemistry</i> , 1998, 9, 736-743.	1.8	17